Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · IEX Real-Time Price · USD
15.72
-0.24 (-1.50%)
Jul 22, 2024, 10:14 AM EDT - Market open
Pulse Biosciences Employees
Pulse Biosciences had 56 employees as of December 31, 2023. The number of employees decreased by 5 or -8.20% compared to the previous year.
Employees
56
Change (1Y)
-5
Growth (1Y)
-8.20%
Revenue / Employee
n/a
Profits / Employee
-$759,750
Market Cap
971.65M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Avanos Medical | 3,771 |
CareDx | 643 |
BioLife Solutions | 414 |
Bicycle Therapeutics | 284 |
Tarsus Pharmaceuticals | 244 |
Tango Therapeutics | 140 |
Silence Therapeutics | 109 |
Pharvaris | 82 |
PLSE News
- 14 days ago - Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation - Business Wire
- 18 days ago - Pulse Biosciences, Inc. Announces the Closing of its Rights Offering - Business Wire
- 24 days ago - Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering - Business Wire
- 6 weeks ago - Pulse Biosciences, Inc. Announces Commencement of Rights Offering - Business Wire
- 2 months ago - Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 - Business Wire
- 2 months ago - Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting - Business Wire
- 2 months ago - Pulse Biosciences Enhances Executive Leadership Team - Business Wire
- 2 months ago - Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System - Business Wire